U.S. Markets close in 4 hrs 13 mins

Blog Exposure - Aclaris Therapeutics Shares Positive Update on Phase-2 Results after a 3-Month Follow-Up of A-101 45% Topical Solution

Stock Monitor: Aurinia Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Aclaris Therapeutics, Inc. (NASDAQ: ACRS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ACRS as the Company's latest news hit the wire. On March 19, 2018, the Company, which is a dermatologist-led biopharmaceutical organization committed towards identifying, developing, and commercializing innovative therapies for addressing unmet needs in dermatology and immunology, shared positive results from a 3-month, post-treatment, follow-up evaluation period of its twice-weekly placebo-controlled WART-203 Trial of A-101 45% topical solution (A-101 45%). Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), which also belongs to the Healthcare sector as the Company Aclaris Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=AUPH

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Aclaris Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ACRS

Common Warts, An Unmet Medical Need

Common warts is a condition wherein skin cells are infected by human papillomavirus (HPV) and spreads via direct contact or contact with infected surfaces. Common warts, which look like skin-colored papules with a rough surface, mostly occur on hands. At present, common warts, or verruca vulgaris, affects about 22 million Americans. The condition is more prevalent in children than adults. Over 2 million people take treatment for common warts from healthcare professionals every year, mainly due to symptoms such as pain, bleeding, itching, and burning.

As of now, there are no US Food and Drug Administration (FDA)-approved prescription medications for warts. The currently available over-the-counter topical treatments for common warts are slow and hardly effective. These treatments are known to have undesirable outcomes such as scarring or depigmentation, and mostly require repeated visits.

A-101 for Treatment of Warts

A-101 45% topical solution (A-101 45%) is an investigational new drug that is being developed as a prescription treatment for common warts. It comprises proprietary high-concentration hydrogen peroxide topical solution.

WART-203 Study Design

The WART-203 Trial evaluated the safety and efficacy of A-101 45% in comparison to placebo in a randomized, double-blind, vehicle-controlled trial, with a 3-month post-treatment follow-up period. The rationale behind the 3-month follow-up period was to analyze the clinical effect of the twice-weekly treatment regimen for 8 weeks, as well as the durability of the clinical effect.

Earlier, A-101 45% met the trial endpoints related to the reduction and clearance of common warts versus placebo in the 56-day treatment period. Post that, subjects continued with the 3-month follow-up portion of the trial.

The WART-203 trial assessed 159 subjects who self-administered either A-101 45% or placebo twice-weekly for 56 days, for a total of 16 treatments. Of these 159 subjects, 151 subjects were able to complete the 3-month post-treatment follow-up period in compliance with the protocol. It must be noted that each subject reported between one and six warts at baseline. In this trial, the primary efficacy analysis was based on the mean change from baseline in the Physician's Wart Assessment (PWA) scale score at Day 56 (Visit 8) and Day 134 (Visit 13). The PWA score is a four-point scale of the investigators' static assessment of the severity of a target wart at a particular time point.

Significant improvements were noted in common wart reduction and clearance versus placebo among subjects treated with A-101 45% in the 3-month post-treatment follow-up period, i.e. at Day 134.

Study Results

The primary efficacy analysis of the WART-203 trial

  • At Day 56, the mean reduction in PWA score on the target warts was 0.87 points in subjects who received A-101 45% compared to a mean reduction of 0.17 points for the subjects treated with placebo (p<0.001).
  • At Day 134, the mean reduction in PWA score on the target warts was 1.0 point in subjects who received A-101 45%, in comparison to a reduction of 0.39 points for subjects that received placebo, which is a statistically significant result (p = 0.0004).

Secondary and exploratory endpoints of the WART-203 trial

  • At Day 56, subjects who received A-101 45% had 30.2% treated warts that were clear (PWA= 0) compared to 9.2% among subjects in the placebo group (p<0.0001). At Day 134, subjects who received A-101 45% had 39.2% treated warts that were clear compared to 17.2% among subjects in the placebo group (p<0.0001).
  • At Day 56, 25.3% of the subjects who received A-101 45% achieved target wart compared to 2.6% among subjects in the placebo group (p<0.0001). At Day 134, the 37.3% of subjects who received A-101 45% achieved target wart clearance compared to 11.8% among subjects in the placebo group (p<0.0002).
  • At Day 56, the proportion of subjects with all treated wart(s) clear (PWA= 0), stratified by the baseline number of warts treated (1-6), was 19.0% for those who received A-101 45%. This was substantially higher than 2.6% for subjects in the placebo group (P=0.001). At Day 134, the proportion of subjects with all treated wart(s) clear, stratified by the baseline number of warts treated (1-6), was 33.3% for those who received A-101 45% compared to 7.9% for subjects in the placebo group (P=0.0002).

Safety Results

No treatment-related serious adverse events were observed among subjects treated with A-101 45%.

Stock Performance Snapshot

March 20, 2018 - At Tuesday's closing bell, Aclaris Therapeutics' stock was slightly up 0.45%, ending the trading session at $17.96.

Volume traded for the day: 237.62 thousand shares.

After yesterday's close, Aclaris Therapeutics' market cap was at $558.56 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

  • Ken Langone: 'Who the hell in their right frame of mind would be buying bonds now?'
    Business
    Yahoo Finance

    Ken Langone: 'Who the hell in their right frame of mind would be buying bonds now?'

    Billionaire investor and philanthropist Ken Langone, the founder of The Home Depot (HD) and chairman of Invemed Associates, argued that there’s some “big time” structural problems in the market right now. “A big fear to me is who the hell in their right frame of mind would be buying bonds now?

  • What Is AT&T’s Outlook after the Major Market Sell-Off?
    Business
    Market Realist

    What Is AT&T’s Outlook after the Major Market Sell-Off?

    What Investors Should Know about AT&T’s Growth Prospects (Continued from Prior Part) Shareholder returns and stock trends AT&T (T) stock fell ~3.4% on October 11 and closed at $31.75 as part of the significant sell-off in the tech sector. Based on that

  • IBM disappoints, more Facebook accusations, Apple apologizes
    Business
    Yahoo Finance

    IBM disappoints, more Facebook accusations, Apple apologizes

    Here’s a look at some of the companies the Yahoo Finance team will be watching for you today. IBM investors aren’t thrilled with the latest earnings report. The company posted a beat on earnings but revenue missed. CEO Ginni Rometty says the results show

  • Steven Mnuchin, Who Sat on Sears' Board for Years, Could Impact the Pensions of Thousands of Workers
    Business
    Fortune

    Steven Mnuchin, Who Sat on Sears' Board for Years, Could Impact the Pensions of Thousands of Workers

    Long before he was Secretary of the Treasury, Steven Mnuchin was a student at Yale University. One of those was Eddie Lampert. Lampert, of course, is the recently departed CEO of Sears Holdings, which filed for Chapter 11 bankruptcy Monday.

  • Pot Stocks Tumble in First Hours of Canada’s Legal Weed Market
    Business
    Bloomberg

    Pot Stocks Tumble in First Hours of Canada’s Legal Weed Market

    (Bloomberg) -- Investor enthusiasm for cannabis stocks cooled Wednesday as Canada’s legalization of adult use went into effect, dipping into a two month rally in the sector.Aurora Cannabis Inc. was among the worst decliners on Wednesday shortly after

  • Why Walmart (WMT) Could Beat Earnings Estimates Again
    Finance
    Zacks

    Why Walmart (WMT) Could Beat Earnings Estimates Again

    Supermarkets industry. When looking at the last two reports, this world's largest retailer has recorded a strong streak of surpassing earnings estimates. For the most recent quarter, Walmart was expected to post earnings of $1.21 per share, but it reported $1.29 per share instead, representing a surprise of 6.61%.

  • Why Marijuana Stocks Cronos Group, Canopy Growth, and Tilray Jumped Today
    Business
    Motley Fool

    Why Marijuana Stocks Cronos Group, Canopy Growth, and Tilray Jumped Today

    The stock market pulled back on Monday, with major benchmarks failing to build on the positive momentum from last Friday. Cronos Group (NASDAQ: CRON), Canopy Growth (NYSE: CGC), and Tilray (NASDAQ: TLRY) were among the best performers. All three of these stocks have something in common: They all stand to benefit from Wednesday's effective date for legal sales of recreational cannabis product in Canada.

  • 7 Stocks to Buy and Hold Through Any Market Selloff
    Business
    InvestorPlace

    7 Stocks to Buy and Hold Through Any Market Selloff

    Last week’s market collapse made headlines throughout the world. Since the sharp correction has negatively impacted virtually all investment sectors, you’re going to find discounted deals everywhere you look.

  • Campbell Soup heirs support current board
    CPB
    CNBC Videos

    Campbell Soup heirs support current board

    CNBC's 'Squawk on the Street' team reports on Campbell Soup's John Durant heirs announcing that they do support the company's current board in a press release on Wednesday morning.

  • Boeing delivers first 737 Max 8 BBJ and unveils Max 7 luxury interior (Photos)
    Business
    American City Business Journals

    Boeing delivers first 737 Max 8 BBJ and unveils Max 7 luxury interior (Photos)

    Boeing has delivered its very first 737 Max 8 business jet to a paying customer. It's the first of 20 BBJ Max jets that buyers from around the world have ordered from the Chicago-based jetmaker since they went on sale. Boeing spokesman Dmitry Krol declined to identify the buyer of the jet, which is the second of its kind made at Boeing's Renton 737 factory.

  • Finance
    TheStreet.com

    General Electric Rises on Reported Iraq Power-Generation Deal

    for a multi-billion-dollar deal to supply power to Iraq. Munich-based Siemens had been close to securing a contract to supply 11 gigawatts of power-generation equipment to Iraq, a deal worth about $15 billion, but then the Trump administration intervened on behalf of GE, the Financial Times reported, citing unnamed people familiar with the matter. The Trump administration reportedly pressured the Iraqi government, and now "GE is expected to take a substantial share of the sale," the Financial Times said.

  • Prince Harry and Meghan Markle's Child Will Probably Not Be a Prince or Princess. Here's What the Title Will Be Instead
    News
    Time

    Prince Harry and Meghan Markle's Child Will Probably Not Be a Prince or Princess. Here's What the Title Will Be Instead

    Prince Harry and Meghan, Duchess of Sussex announced Monday they are expecting their first child and many Brits have responded with the same enthusiasm that met news of Prince William and Kate Middleton’s impending arrivals: Prince George, Princess Charlotte and Prince Louis. “At the time, there were revolutions happening across Europe and many monarchies collapsing,” she says.

  • Is Wells Fargo & Company a Buy?
    Business
    Motley Fool

    Is Wells Fargo & Company a Buy?

    North America's biggest banks have made for pretty great investments over the past few years. Since the beginning of 2016, Bank of America Corp. (NYSE: BAC) and JPMorgan Chase & Co. (NYSE: JPM) have delivered total returns of 72% and 75%, respectively

  • Better Buy: The Home Depot, Inc. vs. Lowe's
    Business
    Motley Fool

    Better Buy: The Home Depot, Inc. vs. Lowe's

    Home Depot (NYSE: HD) and Lowe's (NYSE: LOW) have helped countless homeowners increase the value of their homes. They've also made many investors rich. With their shares having soared 879% and 484%, respectively, over the past decade, Home Depot and Lowe

  • Cramer reveals 5 health-care stocks he likes right now, i...
    Business
    CNBC Videos

    Cramer reveals 5 health-care stocks he likes right now, i...

    Jim Cramer continues his "power rankings" with the health-care sector. His stock picks include a hospital operator, an animal health play and a medical robot maker.

  • Analysts Give Philip Morris a ‘Buy’ Rating before Its Q3 Earnings
    Business
    Market Realist

    Analysts Give Philip Morris a ‘Buy’ Rating before Its Q3 Earnings

    Can Philip Morris Outperform Analysts’ Expectations in Q3 2018? Of the 19 analysts that follow Philip Morris International (PM), 52.6% recommend a “buy,” 42.1% recommend a “hold,” and 5.3% recommend a “sell.” On average, analysts have set a price target of $91.69, which represents a potential return of 11.4% from its current stock price of $82.31. Berenberg cut PM’s target price from $85.00 to $84.00 on October 1.

  • Social Security Checks Are Increasing: What Does That Mean For You?
    Business
    Fortune

    Social Security Checks Are Increasing: What Does That Mean For You?

    Social Security checks will see their biggest increase in four years as 2019 kicks off. The Social Security Administration has approved a 2.8% cost of living adjustment (COLA) for next year. That follows a 2% jump this year and an increase of just

  • Elon Musk says he's going to buy $20 million of Tesla stock
    Business
    CNBC

    Elon Musk says he's going to buy $20 million of Tesla stock

    Tesla (TSLA) Chief Executive Elon Musk told the electric car company that he plans to purchase $20 million of common stock during the next open trading window, according to a filing related to the CEO's settlement with the Securities and Exchange Commission. "Separate and apart from the settlement, Elon has notified Tesla that he intends to purchase from Tesla, and Tesla expects that it will issue and sell to Elon, $20 million of Tesla's common stock during the next open trading window at the then-current market price," the filing read.

  • 3 Stocks for Warren Buffett Fans
    Business
    Motley Fool

    3 Stocks for Warren Buffett Fans

    Warren Buffett has no shortage of acolytes, and it's easy to see why. The Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B) chief and founder has made thousands of early investors in his conglomerate rich as the parent of businesses like GEICO car insurance and Burlington Northern Santa Fe railroad has posted average annual returns of 20% over the last 50 years, crushing the market. Buffett has never gotten too big for his britches, however.

  • Netflix bulls are ignoring a very bearish detail in the streaming giant's numbers
    Finance
    Yahoo Finance

    Netflix bulls are ignoring a very bearish detail in the streaming giant's numbers

    With Netflix long ago earning the momentum trade moniker, the last thing traders want is to be negatively surprised on an earnings release. Streaming media beast Netflix reported Tuesday that through the nine months ended Sept. 30 its free cash flow was an astounding $1.7 billion outflow. Free cash flow is defined as cash flow from operations minus capital expenditures.

  • Even With $80 Oil, You Should Avoid These 3 Stocks
    Business
    Motley Fool

    Even With $80 Oil, You Should Avoid These 3 Stocks

    Three oil and gas stocks that truly stick out as companies with a "stay away" label are independent oil and gas producer SandRidge Energy (NYSE: SD), equipment and services provider Weatherford International (NYSE: WFT), and pipelines and logistics specialist Buckeye Partners (NYSE: BPL).

  • These are the bad things about early retirement that no one talks about
    News
    MarketWatch

    These are the bad things about early retirement that no one talks about

    For all the glamour of living an early retirement lifestyle, there are plenty of negatives I’ve come to discover since I permanently left my job in 2012. As a result, you’re repeatedly forced to will yourself into action.

  • Business
    Reuters

    U.S. Bancorp profit beats on higher interest income, loan growth

    (Adds details on Q3 earnings) Oct 17 (Reuters) - Regional lender U.S. Bancorp reported a better-than-expected quarterly profit on Wednesday, helped by higher interest income and loan growth. A strong economy has led the U

  • Canada Greets Legal Cannabis With Lineups and a ‘Wake and Bake’
    Business
    Bloomberg

    Canada Greets Legal Cannabis With Lineups and a ‘Wake and Bake’

    Stores in St. John’s, Newfoundland were the first to sell recreational cannabis, followed by more than 100 outlets and websites opening across the country of 37 million people. “I’m super happy, this is an historic day for Canadians and for the world because we’re really setting a precedent here," said Isaac Langille outside a store in Halifax where he bought the legal limit of 30 grams, spending C$344 ($264) on products from Aphria Inc. and Organigram Holdings Inc.

  • Price Target Update for Canopy Growth in October
    Business
    Market Realist

    Price Target Update for Canopy Growth in October

    How Analysts Rate These Cannabis Stocks in October (Continued from Prior Part) Canopy Growth Without a doubt, Canopy Growth (CGC)(WEED) has been one of the hottest cannabis stocks on the market (MJ). The company is one of the most valuable companies,